曾洁媛;殷琼洲;王雷;李家洪;张莹;王丽春;李琦涵;杭连菊;车艳春;

• 1:中国医学科学院北京协和医学院医学生物学研究所云南省重大传染病疫苗研发重点实验室
• 2:湖北省疾病预防控制中心
• 3:湖北省襄州区疾病预防控制中心
• 4:湖北省襄阳市疾病预防控制中心

摘要(Abstract)：

目的观察肠道病毒71型(entervirus type 71,EV71)灭活疫苗(人二倍体细胞)适龄接种儿童柯萨奇病毒A组6型(Coxsackievirus A6,CVA6)血清中和抗体变化情况。方法收集EV71灭活疫苗接种儿童的免疫前及免疫后血清,采用微量中和试验检测抗EV71和CVA6中和抗体滴度。结果无手足口病(hand,foot and mouth disease,HFMD)疾病史及EV71灭活疫苗接种史的6～71月龄儿童的血清抗EV71及抗CVA6中和抗体阳性率分别为27.93%和33.91%,共同阳性率为15.32%;两种抗体阳性率总体呈随月龄增加而逐渐升高的趋势(EV71:χ²=4.436,P <0.001;CVA6:χ2=4.436,P <0.001;CVA6:χ²=2.083,P=0.037)。完成EV71灭活疫苗2剂免疫后,抗EV71及抗CVA6中和抗体共同阳性率由15.32%升至32.74%,4个年龄组的抗体共同阳性率也分别由0.00%、8.33%、8.33%和31.11%上升至23.81%、28.00%、13.04%和50.00%;抗EV71中和抗体阳性率(27.93%vs. 98.23%;χ2=2.083,P=0.037)。完成EV71灭活疫苗2剂免疫后,抗EV71及抗CVA6中和抗体共同阳性率由15.32%升至32.74%,4个年龄组的抗体共同阳性率也分别由0.00%、8.33%、8.33%和31.11%上升至23.81%、28.00%、13.04%和50.00%;抗EV71中和抗体阳性率(27.93%vs. 98.23%;χ²=119.257,P <0.001)和几何平均滴度(geometric mean titer,GMT)(7.01 vs. 46.52;χ2=119.257,P <0.001)和几何平均滴度(geometric mean titer,GMT)(7.01 vs. 46.52;χ²=78.730,P <0.001)均较免疫前明显上升;而抗CVA6中和抗体阳性率在免疫前后均为33.91%(χ2=78.730,P <0.001)均较免疫前明显上升;而抗CVA6中和抗体阳性率在免疫前后均为33.91%(χ²=0.000,P> 0.05),GMT在免疫前后差异也无统计学意义(3.09 vs. 4.10;χ2=0.000,P> 0.05),GMT在免疫前后差异也无统计学意义(3.09 vs. 4.10;χ²=0.883,P=0.348)。结论 EV71灭活疫苗适龄接种人群EV71及CVA6的隐性感染率和共同隐性感染率较高。接种EV71灭活疫苗对适龄儿童的抗CVA6中和抗体水平无影响,表明EV71和CVA6之间无中和交叉反应。

关键词(KeyWords)： 肠道病毒71型;灭活疫苗;柯萨奇病毒A组6型;中和抗体;隐性感染

Abstract:

Keywords:

基金项目(Foundation): 云南省重大科技专项计划（2017ZF020）;; 中国医学科学院医学与健康科技创新工程项目（2016-I2M-1-019）

作者(Authors): 曾洁媛;殷琼洲;王雷;李家洪;张莹;王丽春;李琦涵;杭连菊;车艳春;

DOI: 10.13200/j.cnki.cjb.003453

参考文献(References)：

• [1]National Health Commission of the People′s Republic of China.Hand,foot and mouth disease diagnosis and treatment guidelines(2010 edition)[J].Int J Respir,2010,30(24):1473-1475.(in Chinese）中华人民共和国卫生部.手足口病诊疗指南（2010版）[J].国际呼吸杂志，2010,30(24):1473-1475.
• [2]XING W,LIAO Q,VIBOUD C,et al.Hand,foot,and mouth disease in China,2008-12:an epidemiological study[J].Lancet Infect Dis,2014,14(4):308-318.
• [3]SOLOMON T,LEWTHWAITE P,PERERA D,et al.Virology,epidemiology,pathogenesis,and control of enterovirus 71[J].Lancet Infect Dis,2010,10(11):778-790.
• [4]KELLY F,ILAN Y,HUANG J,et al.Hand,foot,and mouth disease caused by Coxsackievirus A6[J].Emerg Infect Dis,2012,18(10):1702-1704.
• [5]European Centre for Disease Prevention and Control(ECDC).Outbreak of enterovirus A71 with severe neurological symptoms among children in Catalonia,Spain 14 June 2016.Stockholm:ECDC,2016.
• [6]ANTONA D,KOSSOROTOFF M,SCHUFFENECKER I,et al.Severe paediatric conditions linked with EV-A71 and EV-D68,France,May to October 2016[J].Eurosurveillance,2016,21(46):30402.
• [7]TIAN H,ZHANG Y,SHI Y,et al.Epidemiological and aetiological characteristics of hand,foot,and mouth disease in Shijiazhuang City,Hebei province,China,2009-2012[J].Plo S One,2017,12(5):e0176604.
• [8]HAN J F,XU S,ZHANG Y,et al.Hand,foot,and mouth disease outbreak caused by coxsackievirus A6,China,2013[J].J Infect,2014,69(3):303-305.
• [9]LU J,ZENG H,ZHENG H,et al.Hand,foot and mouth disease in Guangdong,China,in 2013:new trends in the continuing epidemic[J].Clin Microbiol Infect,2014,20 (7):O442-O445.
• [10]HONGYAN G,CHENGJIE M,QIAOZHI Y,et al.Hand,foot and mouth disease caused by coxsackievirus a6,beijing,2013[J].Pediatr Infect Dis J,2014,33(12):1302.
• [11]LI J L,YUAN J,YANG F,et al.Epidemic characteristics of hand,foot,and mouth disease in southern China,2013:coxsackievirus A6 has emerged as the predominant causative agent[J].J Infect,2014,69(3):299-303.
• [12]DI B,ZHANG Y,XIE H,et al.Circulation of Coxsackievirus A6 in hand-foot-mouth disease in Guangzhou,2010-2012[J].Virol J,2014,11(1):157.
• [13]MAO Q Y,BIAN L L,WANG Y D.New trends for pathogen spectrum of hand,foot and mouth disease and research of vaccines in China[J].Chin J Biologicals,2015,28(9):979-984.(in Chinese）毛群颖，卞莲莲，王一平.我国手足口病病原谱以及疫苗研究新动态[J].中国生物制品学杂志，2015,28(9):979-984.
• [14]JR H M F,BENNETT N,MODLIN J F.Atypical hand,foot,and mouth disease:a vesiculobullous eruption caused by Coxsackie virus A6[J].Lancet Infect Dis,2014,14(1):83-86.
• [15]CHEN B,YU G Q,RAO D P,et al.A prevalence survey and analysis of risk factors on subclinical infection of the EV71 and Cox A16 in healthy children in nurseries[J].J Trop Med,2013,13(4):496-498.(in Chinese）陈兵，余光清，饶东平，等.托幼机构健康儿童EV71和Cox A16隐性感染的现况调查及危险因素分析[J].热带医学杂志，2013,13(4):496-498.
• [16]CHEN R L,PAN R Y,LAI Z F,et al.The microneutralization assay for the detection of neutralizing antibodies against EV71and CVA16 among healthy population[J].Chin Prev Med,2013(5):362-365.(in Chinese）陈润莉，潘瑞胤，赖植发，等.微量细胞病变法检测健康人群EV71和CVA16中和抗体水平[J].中国预防医学杂志，2013(5):362-365.
• [17]LI Y,JIANG M,ZHANG Y Y,et al.Analysis of EV71 and CVA16 serum specific antibodies in health children from kindergarten in areas of Guangxi province[J].J Trop Dis Parasitol,2017,15(2):99-101.(in Chinese）李燕，蒋敏，张艳艳，等.广西健康幼托儿童EV71和CVA16血清抗体水平分析[J].热带病与寄生虫学，2017,15(2):99-101.
• [18]WANG H Y.Etiological surveillance of HFMD and survey on the enterovirus distribution in healthy person[D].Hefei:Anhui Medical University,2014.(in Chinese）王宏宇.手足口病病原谱监测及肠道病毒在正常人群中的调查研究[D].安徽合肥：安徽医科大学，2014.
• [19]GUO X B,ZHU S L,WANG D Y,et al.Seroepidemiology investigation of HEV71 in healthy children of 1~6 years old in three counties[J].Chin J Vaccin Immun,2009(2):141-144.(in Chinese）郭学斌，祝双利，王东艳，等.2005年中国3个县1~6岁儿童人肠道病毒71型血清流行病学调查[J].中国疫苗和免疫，2009(2):141-144.
• [20]SUN B C,GAO J,CHEN D,et al.Study on the recessive infection of hand,foot and mouth disease(HFMD) virus in children[J].Pract Prev Med,2014,21(8):914-916.(in Chinese）孙宝昌，高娟，陈栋，等.儿童手足口病病毒隐性感染情况研究[J].实用预防医学，2014,21(8):914-916.
• [21]YAN Y B,ZHENG H N,SU C H.Recessive infection status after the outbreak of hand-foot-mouth disease in kindergartens[J].Chin J Sch Health,2016,37(2):250-252.(in Chinese）颜玉炳，郑惠能，苏成豪.幼托机构手足口病暴发疫情后儿童隐性感染情况[J].中国学校卫生，2016,37(2):250-252.
• [22]YUAN W,CHEN X W,LIU Y Q,et al.Subclinical Infection of Hand-foot-mouth disease in healthy kindergarten children and influencing factors[J].J Prev Med Inf,2018,34 (8):1062-1065.(in Chinese）袁伟，程秀伟，刘雅琼，等.健康儿童手足口病隐性感染情况及影响因素分析[J].预防医学情报杂志，2018,34(8):1062-1065.
• [23]LIU L,MO Z,LIANG Z,et al.Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children:a report of further observations[J].BMC Med,2015,13(1):1-10.
• [24]CHOU A H,LIU C C,CHANG J Y,et al.Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1,B4,B5 and C4A in adult volunteers[J].PLo S One,2013,8(11):e79783.
• [25]MAO Q,CHENG T,ZHU F,et al.The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children[J].PLo S One,2013,8(11):e79599.
• [26]LI R,LIU L,MO Z,et al.An inactivated enterovirus 71 vaccine in healthy children[J].N Engl J Med,2014,370(9):829.
• [27]ZHU F,XU W,XIA J,et al.Efficacy,safety,and immunogenicity of an enterovirus 71 vaccine in China[J].N Engl JMed,2014,370(9):818-828.